VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 27, 2014) - CAVAN VENTURES INC. (TSX VENTURE:CVN) ("Cavan" or the "Company") is pleased to provide a corporate update in regards to the continuing exploration of the potential of the Medical Marijuana and Hemp/Cannabinoid industry.
Cavan Ventures Inc. previously announced (see news release dated 2014-03-25) the diversification of its growth plan into the Medical Marijuana and Hemp industry. To accelerate this process, Matthew Harvey has joined the Company as its newest member to the advisory board.
Mr. Harvey has been a master grower and in the industry since the mid 1990's with world-wide exposure since 2004. Mr. Harvey is the Founder and CEO of BC Bud Depot ("BCBD"), a producer of marijuana seeds. BCBD takes pride in developing its award-winning THC and CBD cannabis strains. BCBD also collaborates with other breeders and dispensaries (including Reeferman Seeds, T.H.Seeds and DNA Genetics, and to European breeders like Soma Seeds and Delta-9 labs, and California's The Honey Spot), and offers over 50 proprietary medicinal strains to date with access to over 150 marijuana strains collaborated together with associated partners. During Mr. Harvey's tenure, BCBD has received over 21 Cannabis Cup awards, including 7 first place awards, 9 Top Strain awards, 6 top 3 strain awards and an induction in 2009 to the Seed Bank Hall of Fame award. Additionally, BC Bud Depot has outreach to over 11 North American dispensaries and over 60 worldwide retail and web stores which stock BCBD'S products. Most recently, Mr. Harvey has steered BCBD towards a new developmental approach to medicinal genetics, producing unique strains to be used for specific medical ailments.
Peter P. Swistak, President/CEO of Cavan Ventures Inc., states, "The depth and scope of Mr. Harvey's knowledge is unparalleled and Cavan is very fortunate to have access to this knowledge as we believe he is the best in his field with an extensive bio and proven track record. He will add tremendous value, credibility and unique knowledge to Cavan in its analysis of the Medical Marijuana and Hemp/Cannabinoid industry, and potential opportunities in that industry. We are excited to have Mr. Harvey available to us while we conduct due-diligence in the Cannabinoid/Medicinal Marijuana space."
At this time, no transactions are in place, nor is there any assurance that a new project will be concluded in the future.
For more information visit the website at www.cavanventuresinc.com.
ON BEHALF OF THE BOARD
Peter P. Swistak, President